<code id='C0640FB844'></code><style id='C0640FB844'></style>
    • <acronym id='C0640FB844'></acronym>
      <center id='C0640FB844'><center id='C0640FB844'><tfoot id='C0640FB844'></tfoot></center><abbr id='C0640FB844'><dir id='C0640FB844'><tfoot id='C0640FB844'></tfoot><noframes id='C0640FB844'>

    • <optgroup id='C0640FB844'><strike id='C0640FB844'><sup id='C0640FB844'></sup></strike><code id='C0640FB844'></code></optgroup>
        1. <b id='C0640FB844'><label id='C0640FB844'><select id='C0640FB844'><dt id='C0640FB844'><span id='C0640FB844'></span></dt></select></label></b><u id='C0640FB844'></u>
          <i id='C0640FB844'><strike id='C0640FB844'><tt id='C0640FB844'><pre id='C0640FB844'></pre></tt></strike></i>

          Home / knowledge / comprehensive

          comprehensive


          comprehensive

          author:comprehensive    Page View:474
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In